Physician profile
Cesar Reyes
NPI 1801885959
$1,170.79
in general payments reported to CMS, 2019-2025
24 companies · $36.76 in 2025
The $36.76 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $191 · 2021: $33.16 · 2022: $382 · 2023: $183 · 2024: $101 · 2025: $36.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291.34 | 2019-2025 | |
| Exeltis, USA INC. | $129.24 | 2019-2021 | |
| Organon LLC | $91.65 | 2022-2024 | |
| Millicent US INC | $82.44 | 2019-2025 | Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $71.28 | 2022 | |
| Sumitomo Pharma America, INC. | $66.31 | 2023-2024 | Myfembree |
| Avion Pharmaceuticals | $62.58 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $37.51 | 2020-2022 | |
| Aspira Women'S Health INC | $34.99 | 2022-2023 | Ova1 |
| Mylan Pharmaceuticals INC. | $33.13 | 2019 | |
| Shield Therapeutics INC | $30.01 | 2022-2024 | |
| Acessa Health INC. | $27.62 | 2019 | |
| Pfizer INC. | $26.43 | 2019-2020 | |
| Medtronic, INC. | $24.74 | 2024 | Truclear |
| Bayer Healthcare Pharmaceuticals INC. | $24.18 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21.80 | 2023 | Proclaim |
| Myovant Sciences INC. | $18.72 | 2022 | |
| Hologic Sales and Service, LLC | $18.67 | 2019 | |
| Ascend Therapeutics US, LLC | $18.58 | 2022 | |
| Covidien LP | $18.11 | 2020 | |
| Agile Therapeutics, INC. | $15.41 | 2022 | |
| Astellas Pharma US INC | $14.95 | 2023 | Myrbetriq |
| Lupin INC. | $11.10 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.